Last checked at 16 Jan 2024 08:15
UBS downgrades AstraZeneca to 'sell'
(Sharecast News) - UBS has downgraded AstraZeneca and upgraded rival GSK as part of its latest review of the European pharmaceutical sector.
Read more
- Home
- Share Prices
- AQSE Share Prices
- Euronext
- Stock Screeners
- Share Chat
- FX
- News & RNS
- Events
- Media
- Trading Brokers
- Finance Tools
- Members
Latest Share Chat
Astrazeneca Share News (AZN)
AZN Share
Price
AZN Share
News1
AZN Share
Chat
AZN Share
Trades
AZN
Live RNS
AZN Share
Charts
AZN Level 2
Console
AZN Live
Share Price
AZN Broker
Ratings
AZN Directors
Deals
AZN Financial
Diary
AZN
Fundamentals
AZN Short
Positions
AZN
Media
Astrazeneca Information
Share Price Information for Astrazeneca (AZN)
Share Price is delayed by 15 minutes
Get Live Data
Share Price:
12,050.00
Bid:
12,038.00
Ask:
12,040.00
Change:
0.00 (0.00%)
Spread:
2.00 (0.017%)
Open:
0.00
High:
0.00
Low:
0.00
Prev. Close:
12,050.00
Last checked at -
Watchlists are a member only feature
Login to your account
Don't have an account? Click here to register.AstraZeneca gets positive breast cancer trial results; potassium drug suffers setback
Fri, 27th May 2016 07:32
(ShareCast News) - Phamaceuticals giant AstraZeneca announced positive results for its Faslodex drug for the treatment of metastatic breast cancer, but also said US regulators will not currently approve its new drug for high potassium levels because of a manufacturing issue.The company said on Friday that Faslodex met its primary endpoint of extended progression-free survival in post-menopausal women who have not had prior hormonal treatment for home-receptor-positive breast cancer. Sean Bohen, executive vice president of Global Medicines Development and chief medical officer at AstraZeneca, said: "The FALCON results bring us closer to offering more and earlier treatment options to postmenopausal women with HR+ locally-advanced or metastatic breast cancer; the potential to delay disease progression is important for these patients as there is currently no cure."Faslodex has over 10 years of clinical evidence and we are committed to exploring its potential along with the rest of our outstanding oncology portfolio"Also on Friday, AZN said the US Food & Drug Administration would not approve one of its new drugs because of a manufacturing problem.It said the FDA has issued a complete response letter (CRL) on the new drug application made for sodium zirconium cyclosilicate, the investigational medicine being developed for the treatment of hyperkalaemia (high potassium level in the blood serum) by wholly-owned subsidiary ZS Pharma.The CRL refers to observations arising from a pre-approval manufacturing inspection. The FDA also acknowledged receipt of recently-submitted data which it has yet to review and said it does not require the generation of new clinical data."AstraZeneca and ZS Pharma are evaluating the content of the CRL and will work closely with the FDA to determine the appropriate next steps for the NDA."Societe Generale said the response from the FDA will probably delay launch by around six months to the second half of 2017."We spoke to AZN LN this morning. The group appears confident it can resolve these issues smoothly and swiftly. Our impression is that the FDA may be being overly vigilant. Nonetheless this news is unhelpful as ZS9 only entered AZN LN's pipeline in Q4 16 via the $3bn acquisition of ZS Pharma."Still, the bank said the news does not change its medium-term positive investment case on the stock, which it rates at 'buy'.At 0930 BST, AZN shares were down 0.3% to 3,998.50p.
More News
9 Jan 2024 10:50
Novartis in advanced talks to buy Cytokinetics- source
Jan 9 (Reuters) - Swiss drugmaker Novartis is in the lead to acquire Cytokinetics in a deal that could value the drug developer at well over $10 billion, a source familiar with the matter said on Monday.
Read more8 Jan 2024 14:08
Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference
NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.
Read more6 Jan 2024 17:44
Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference
NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.
Read more5 Jan 2024 12:00
Late M&A bonanza stokes healthcare dealmakers ahead of JPMorgan conference
NEW YORK, Jan 5 (Reuters) - Healthcare dealmakers are making their way to San Francisco for a major industry conference, optimistic that more deals are in the offing after a wave of biotech company takeovers at the end of last year.
Read more3 Jan 2024 17:48
London close: Stocks fall amid rising geopolitical concerns
(Sharecast News) - London stocks closed lower on Wednesday - the 40th anniversary of the FTSE 100's launch - as sentiment remained cautious due to increasing tensions in the Middle East.
Read more3 Jan 2024 16:52
LONDON MARKET CLOSE: Stocks down ahead of US Fed minutes
(Alliance News) - Stock prices in London closed lower on Wednesday, as investors nervously look ahead to the latest US Federal Reserve meeting minutes.
Read more3 Jan 2024 11:07
Jefferies upgrades GSK to 'buy', cuts AstraZeneca to 'hold'
(Sharecast News) - Jefferies has upgraded its rating on GlaxoSmithKline to 'buy' and cut AstraZeneca to 'hold' as part of its review of the European pharma sector.
Read more3 Jan 2024 10:16
IN BRIEF: Nuformix narrows annual loss as develops drug assets
Nuformix PLC - London-based developer of treatments for fibrosis and oncology via drug repurposing - Pretax loss narrows to GBP927,972 in 18 months that ended September 30 from GBP1.3 million in the 12 months that ended March 31, 2022, following its change of financial year-end. Has no meaningful revenue in either period, so reduced loss is due to lower administrative expenses.
Read more3 Jan 2024 10:12
AIM WINNERS & LOSERS: C4X gets Astra payment; Getech wins eight deals
(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Wednesday.
Read more3 Jan 2024 09:23
LONDON BROKER RATINGS: GSK raised to 'buy'; AstraZeneca cut to 'hold'
(Alliance News) - The following London-listed shares received analyst recommendations Wednesday morning and Tuesday:
Read more3 Jan 2024 08:58
LONDON MARKET OPEN: Stocks mixed pre-Fed minutes, amid Asia losses
(Alliance News) - Stock prices in London opened mixed on Wednesday, ahead of US Federal Reserve meeting minutes and manufacturing PMI data for the US in the evening and afternoon respectively.
Read more3 Jan 2024 08:04
C4X receives USD11 million from AstraZeneca following NRF2 trials
(Alliance News) - C4X Discovery Holdings PLC on Wednesday said it has received payment from AstraZeneca PLC following trials of the C4X respiratory disease therapy treatment.
Read more3 Jan 2024 07:54
LONDON BRIEFING: Stocks to open flat pre-Fed minutes, jobs data
(Alliance News) - The FTSE 100 is expected to open flat on Wednesday, as London's flagship index celebrates its 40th anniversary, after mostly downbeat trading in Asia and a tech sell-off in New York.
Read more2 Jan 2024 17:05
British equities slip on higher yields, financials drag
FTSE 100 down 0.2%, FTSE 250 off 0.9%
*Read more